| Code | CSB-RA013481MB8HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Posdinemab, targeting microtubule-associated protein tau (MAPT). MAPT plays a critical role in stabilizing microtubules in neurons and regulating axonal transport. Under pathological conditions, tau undergoes hyperphosphorylation and aggregates into neurofibrillary tangles, a hallmark of Alzheimer's disease and other tauopathies including frontotemporal dementia, progressive supranuclear palsy, and chronic traumatic encephalopathy. Abnormal tau accumulation correlates with neurodegeneration and cognitive decline, making it a key therapeutic target in neurodegenerative disease research.
Posdinemab is a humanized monoclonal antibody designed to target pathological forms of tau protein and has been investigated in clinical trials for Alzheimer's disease. This biosimilar provides researchers with a valuable tool for studying tau biology, investigating tau-mediated neurotoxicity mechanisms, and evaluating potential therapeutic interventions in tauopathy models. It supports investigations into protein aggregation pathways, neuroinflammatory responses, and disease progression in neurodegenerative disorders.
There are currently no reviews for this product.